Prolactin-related and metabolic adverse effects of atypical antipsychotic agents

Journal of Clinical Psychiatry

Volumn 69, Issue SUPPL. 1, 2008, Pages 32-44

  Henderson, David C ^a,b,d   Doraiswamy, P Murali ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLYCOSYLATED HEMOGLOBIN; HALOPERIDOL; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

AMENORRHEA; APPETITE; BIPOLAR MANIA; BLOOD PRESSURE MONITORING; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; GALACTORRHEA; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; HYPOPHYSIS TUMOR; LIPID BLOOD LEVEL; LIPIDOMICS; METABOLIC SYNDROME X; METABOLOMICS; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN; ADULT; BIPOLAR DISORDER; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; HYPERCHOLESTEROLEMIA; MASS SCREENING; METABOLISM; WAIST HIP RATIO;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERCHOLESTEROLEMIA; HYPERPROLACTINEMIA; HYPERTENSION; MASS SCREENING; METABOLIC SYNDROME X; PROLACTIN; SCHIZOPHRENIA; WAIST-HIP RATIO; WEIGHT GAIN;

EID: 45749088608     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64:2291-2314
2. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Report Med 2002;20:365-374
3. Perkins DO. Antipsychotic-induced hyperprolactinemia: pathophysiology and clinical consequences. Adv Stud Med 2004;4:S982-S986
4. Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 2007;21:768-773
5. Segal M, Avital A, Derevenski A, et al. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone. Int Clin Psychopharmacol 2007;22:192-196
6. Malik P. Sexual dysfunction in schizophrenia. Curr Opin Psychiatry 2007;20:138-142
7. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006;21:529-532
8. Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005;162:1010-1012
9. Citrome L. Paliperidone: quo vadis? Int J Clin Pract 2007;61:653-662
10. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-130
11. Owen RT. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today (Barc) 2007;43:249-258
12. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-1370
13. Hamner MB, Arana GW. Hyperprolactinemia in antipsychotic-treated patients: guidelines for avoidance and management. CNS Drugs 1998;10:209-222
14. Hyperprolactinaemia associated with effective antipsychotic treatment no longer inevitable. Drugs Ther Perspective 1999;14:11-14
15. Luciano AA. Clinical presentation of hyperprolactinemia. J Reprod Med 1999;44(suppl 12):1085-1090
16. Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980;303:1511-1514
17. Harvey PW. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments. J Appl Toxicol 2005;25:179-183
18. Harvey PW, Everett DJ, Springall CJ. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Hum Exp Toxicol 2006;25:395-404
19. Clevenger CV. Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis 2003;18:75-86
20. Clevenger CV, Furth PA, Hankinson SE, et al. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27
21. Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629-634
22. Yamazawa K, Matsui H, Seki K, et al. A case-control study of endometrial cancer after antipsychotics exposure in premenopausal women. Oncology 2003;64:116-123
23. Dexeus S, Barri PN. Hyperprolactinemia: an inductor of neoplastic changes in endometrium? a report of two cases. Gynecol Endocrinol 1998;12:273-275
24. Wallaschofski H, Kobsar A, Sokolova O, et al. Differences in platelet activation by prolactin and leptin. Horm Metab Res 2004;36:453-457
25. Wallaschofski H, Lohmann T, Hild E, et al. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost 2006;96:38-44
26. Bartke A, Matt KS, Steger RW, et al. Role of prolactin in the regulation of sensitivity of the hypothalamic-pituitary system to steroid feedback. Adv Exp Med Biol 1987;219:153-175
27. Dunbar F, Kusumakar V, Daneman D, et al. Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 2004;161:918-920
28. Steinhagen CK. Normalization of prolactin with aripiprazole in a patient with psychotic depression and a comorbid pituitary microadenoma. Psychosomatics 2007;48:350-351
29. Szarfman A, Tonning JM, Levine JG, et al. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006;26:748-758
30. Colao A, di Sarno A, Pivonello R, et al. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 2002;11:787-800
31. De Hert M, Hanssens L, van Winkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophrenia Bull 2007;33:823-830
32. Keller R, Mongini F. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. Neurol Sci 2002;23:233-235
33. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo controlled trial. Am J Psychiatry 2007;164:1404-1410
34. Adams CE, Awad G, Rathbone J, et al. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2007:CD000284
35. Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007;61:1356-1370
36. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601
37. US Dept of Health and Human Services. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, Md: National Institutes of Health; 2000
38. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26:S5-S20
39. Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone [published online ahead of print 18 July 2007]. Neuropsychopharmacology doi: 10.1038/sj.npp. 1301482
40. Dunican KC, Desilets AR, Montalbano JK. Pharmacotherapeutic options for overweight adolescents. Ann Pharmacother 2007;41(Sept):1445-1455
41. Graham KA, Gu H, Lieberman JA, et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 2005;162:1744-1746
42. Gadde KM, Xiong GL. Bupropion for weight reduction. Expert Rev Neurother 2007;7:17-24
43. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
44. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58(suppl 10):45-49
45. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100
46. Abilify [package insert]. Tokyo, Japan: Otsuka America Pharmaceutical, Inc; 2006. Available at: http://www.otsuka.com/documents/AbilifyFullPI.pdf. Accessed June 6, 2007
47. Geodon [package insert]. New York, NY: Pfizer, Inc; 2007. Available at: http://www.pfizer.com/pfizer/download/uspi_geodon.pdf. Accessed June 6, 2007
48. Brecher M, Zukin S, Leong R, et al. Long-term weight change with quetiapine treatment in schizophrenia: a comprehensive data review. Neuropsychopharmacology 2004;29(suppl 1):S109. Abstract 114
49. Risperdal [package insert]. Titusville, NJ: Janssen, LP; 2007. Available at: http://www.risperdal.com/risperdal/assets/risperdal.pdf. Accessed Dec 6, 2007
50. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421
51. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
52. Casey DE, L'Italien G, Waldeck R, et al. Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo. In: New Research Abstracts of the 156th Annual Meeting of the American Psychiatric Association; May 21, 2003; San Francisco, Calif. Abstract NR733:274-275
53. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(suppl 18):47-56
54. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19-28
55. Kaddurah-Daouk R, McEvoy J, Baillie RA, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007;12:934-945
56. Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163:2072-2079
57. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159:655-657